WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 529014
Description: ZSET-1446, also known as ST-101, is a T-type calcium channel activator potentially for the treatment of Alzheimer's disease and essential tremor.
MedKoo Cat#: 529014
Chemical Formula: C15H12N2O
Exact Mass: 236.095
Molecular Weight: 236.27
Elemental Analysis: C, 76.25; H, 5.12; N, 11.86; O, 6.77
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: ZSET-1446; ST-101; ZSET1446; ST101; ZSET 1446; ST 101
IUPAC/Chemical Name: 1',3'-dihydro-2H-spiro[imidazo[1,2-a]pyridine-3,2'-inden]-2-one
InChi Key: QZWYXEBIQWJXAR-UHFFFAOYSA-N
InChi Code: InChI=1S/C15H12N2O/c18-14-15(17-8-4-3-7-13(17)16-14)9-11-5-1-2-6-12(11)10-15/h1-8H,9-10H2
SMILES Code: O=C1N=C2C=CC=CN2C13CC4=C(C=CC=C4)C3
Appearance: White to off-white solid powder.
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 236.27 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Yamaguchi Y, Takeda K, Hino M. Combination effects of ZSET1446/ST101 with memantine on cognitive function and extracellular acetylcholine in the hippocampus. J Pharmacol Sci. 2013;123(4):347-55. PubMed PMID: 24292380.
2: Yamaguchi Y, Saito K, Matsuno T, Takeda K, Hino M. Effects of ZSET1446/ST101 on cognitive deficits and amyloid β deposition in the senescence accelerated prone mouse brain. J Pharmacol Sci. 2012;119(2):160-6. PubMed PMID: 22790316.
3: Shioda N, Yamamoto Y, Han F, Moriguchi S, Yamaguchi Y, Hino M, Fukunaga K. A novel cognitive enhancer, ZSET1446/ST101, promotes hippocampal neurogenesis and ameliorates depressive behavior in olfactory bulbectomized mice. J Pharmacol Exp Ther. 2010 Apr;333(1):43-50. doi: 10.1124/jpet.109.163535. PubMed PMID: 20068029.
4: Han F, Shioda N, Moriguchi S, Yamamoto Y, Raie AY, Yamaguchi Y, Hino M, Fukunaga K. Spiro[imidazo[1,2-a]pyridine-3,2-indan]-2(3H)-one (ZSET1446/ST101) treatment rescues olfactory bulbectomy-induced memory impairment by activating Ca2+/calmodulin kinase II and protein kinase C in mouse hippocampus. J Pharmacol Exp Ther. 2008 Jul;326(1):127-34. doi: 10.1124/jpet.108.137471. PubMed PMID: 18388258.
5: Yamaguchi Y, Miyashita H, Tsunekawa H, Mouri A, Kim HC, Saito K, Matsuno T, Kawashima S, Nabeshima T. Effects of a novel cognitive enhancer, spiro[imidazo-[1,2-a]pyridine-3,2-indan]-2(3H)-one (ZSET1446), on learning impairments induced by amyloid-beta1-40 in the rat. J Pharmacol Exp Ther. 2006 Jun;317(3):1079-87. PubMed PMID: 16474004.
6: Takeda K, Yamaguchi Y, Hino M, Kato F. Potentiation of Acetylcholine-Mediated Facilitation of Inhibitory Synaptic Transmission by an Azaindolizione Derivative, ZSET1446 (ST101), in the Rat Hippocampus. J Pharmacol Exp Ther. 2016 Feb;356(2):445-55. doi: 10.1124/jpet.115.229021. PubMed PMID: 26578264.
7: Ito Y, Takuma K, Mizoguchi H, Nagai T, Yamada K. A novel azaindolizinone derivative ZSET1446 (spiro[imidazo[1,2-a]pyridine-3,2-indan]-2(3H)-one) improves methamphetamine-induced impairment of recognition memory in mice by activating extracellular signal-regulated kinase 1/2. J Pharmacol Exp Ther. 2007 Feb;320(2):819-27. PubMed PMID: 17090702.
8: Shioda N, Yamamoto Y, Han F, Moriguchi S, Fukunaga K. [Neurochemical mechanisms of a novel Alzheimer's disease therapeutics on improvement of cognition and depressive behavior]. Yakugaku Zasshi. 2011 Apr;131(4):505-11. Review. Japanese. PubMed PMID: 21467789.
9: Green KN, Khashwji H, Estrada T, Laferla FM. ST101 induces a novel 17 kDa APP cleavage that precludes Aβ generation in vivo. Ann Neurol. 2011 May;69(5):831-44. doi: 10.1002/ana.22325. PubMed PMID: 21416488.
10: Moriguchi S, Shioda N, Yamamoto Y, Tagashira H, Fukunaga K. The T-type voltage-gated calcium channel as a molecular target of the novel cognitive enhancer ST101: enhancement of long-term potentiation and CaMKII autophosphorylation in rat cortical slices. J Neurochem. 2012 Apr;121(1):44-53. doi: 10.1111/j.1471-4159.2012.07667.x. PubMed PMID: 22251222.
11: Nagai T, Yamada K. [Molecular mechanism for methamphetamine-induced memory impairment]. Nihon Arukoru Yakubutsu Igakkai Zasshi. 2010 Apr;45(2):81-91. Review. Japanese. PubMed PMID: 20486560.